
Jack McCaffery Takes Leave for Lymphoma Treatment
The University of Richmond basketball player is receiving care at the Hospital of the University of Pennsylvania after a Hodgkin lymphoma diagnosis.
Across the United States, coverage here takes in medical research, drug approvals, public health warnings, wellness practices and insurance coverage. It addresses the personal decisions made about well-being as well as the institutions that facilitate care.

The University of Richmond basketball player is receiving care at the Hospital of the University of Pennsylvania after a Hodgkin lymphoma diagnosis.
Live Poll
Would you pay for a fitness app subscription to build a regular strength routine?
The beta strength training program builds four-week plans and is included in the existing Fitness+ subscription.

A population-based study tracking stroke incidence in Greater Cincinnati and Northern Kentucky finds rising rates among adults aged 20 to 54 through 2020.
Live Poll
Do you trust public health agencies to manage drug-resistant infections like Shigella?
The agency's latest antimicrobial resistance report highlights rising resistance in the severe diarrheal bacteria, which can spread through sexual contact.

Live Poll
Should your community invest more in parks and green spaces near schools?
A Washington University in St. Louis study ties children's proximity to parks and wooded areas to better attention performance.

Live Poll
Should Congress work to strengthen Social Security without cutting earned benefits?
Voters aged 50 and older made up 60% of the 2026 midterm electorate, according to NORC election poll data.

Reporting here centers on clinical findings and the drug approvals that follow, evolving wellness trends, system-wide health insurance changes and public health guidance. It reaches every state and the disparate systems that provide care to the population. Research findings often face scrutiny regarding their long-term clinical efficacy and application in different settings. Shifts in coverage rules and the accessibility of new treatments remain the primary constraints on the health landscape.